Chinese
Japan
English
Home
Biologics Discovery
Antibody Lead Generation
Hybridoma Generation for Therapeutic Antibody Discovery
ProSpeedTM Single B cell Antibody Discovery
Fully Human Antibody Discovery by Transgenic Mice
Human Fab Naïve Library
Solution for Novel Biologics Modalities
Bispecific Antibody DiscoveryNEW!
Innovative SMABody Bispecific Antibody Discovery
CAR Lead Discovery
Single Domain Antibody Discovery
ADC Discovery Service
Antibody Discovery Solution for Multi-pass Membrane Targets
pH-selective Antibody Discovery Service
Antibody Lead Optimization
Antibody Humanization
Antibody Affinity Maturation
Fc Engineering Service
Developability Assessment
Pharmacology & Discovery Reagent Service
In Vitro Pharmacology
ADCC, CDC & ADCP Assay
GPCR-targeted Assay
Cytokine Neutralization Assay
ADC Bioassay Service
Immune Checkpoint Reporter Assay
Immune Checkpoint Primary Cell Assay
Pseudovirus Neutralization Assay Services for SARS-CoV-2
Engineered Cell Line based Bioassay Service
Bispecific Antibody Bioassay ServiceNEW!
In Vivo Pharmacology
In Vivo Efficacy
Pharmacokinetics Study
Toxicology Study
Biomarker testing and bioanalysis
Anti-idiotype Antibody and Immunoassay Development
PK and ADA Assay Development Services
Anti-idiotype antibody case study
Universal PK Tool Antibody Service for Antibody Drug
Affinity Measurement
Biologics CDMO
Fast Sample Preparation
Cell Line Development
ADCC Enhanced Cell Line Development
Host Cell Commercial License
GMP Cell Banking
IND-enabling CMC
Perfusion Process Development
CMC Case Study
Bioanalytical Development
ADCC & CDC Assays
Protein/Ab Characterization
SARS-CoV-2 Neutralizing Antibody In Vitro Bioassay Services
Bioassay Characterization NEW!
Antibody & Protein CMC Solutions for CGT
Process Characterization & Process Validation
200-500L Drug Substance Manufacturing
2000L Drug Substance Manufacturing
Aseptic Fill & Finish
ProBox™ Process Development Tool Box
UproCHO™ Medium System
CGT CDMO
Plasmid CDMO Services
LentiHelperTM Plasmid Products
AAssistVTM Plasmid Products
Plasmid CMC for IND
Plasmid Manufacture
GMProTM Plasmid Manufacturing
Linearized DNA Manufacture
Proprietary PowerS™-ITRrs Strain
Lentiviral Vector CDMO Services
Cell Line for LVV Manufacturing
Cell Banking
ProLVV Manufacturing
Lentiviral Vector One-stop Solution
LVV BLA PC/PV
LVV Manufacturing
AAV Vector CDMO Services
Cell Line for AAV Manufacturing
ProAAV Manufacturing Service
AAV One-stop Solution
AAV Manufacturing
mRNA CDMO Service
mRNA CMC for IND
mRNA Manufacture
News & Activities
GenScript-Thermo Fisher Strategic Partnership on Life Sciences and Biopharma
GenScript Biotech's Biologics R&D and Production Center is Formally Put Into Operation
China's Largest Plasmid and Virus Facility from GenScript was Put into Operation
ABL Bio Inc.- GenScript Biotech Corp Bispecific Antibody Strategic Partnership Agreement Ceremony
Chinese CDMO GenScript starts construction of GenScript-Legend Biotech Commercial Manufacturing Center
GenScript and Selecxine Enter Into Strategic Cooperation Agreement
GenScript launches CDMO segment ProBio at inaugural GenScript Cell and Gene Therapy Industry Development & Cooperation Forum
Beroni Group Signs Agreement with ProBio to Conduct Further Study to Develop Nanobody-based Medical Solution for COVID-19
ProBio American Commercial Head, Kenneth Lee gives interview to The Medicine Maker about How we can help customers optimize their developing and manufacturing processes
ProBio Licensed Global Rights to Develop and Commercialize a SMAB Bispecific Antibody Molecule to REMD Biotherapeutics Inc.
ProBio Congratulates XLifeSc on FDA Allowance of IND Application for TCR-T Program
ProBio Wins Bioprocessing Excellence in CDMO Services from IMAPAC
ProBio Chinese Brand Unveiled, CDMO Capacity Upgraded
Serving a Rising Power
Initium Therapeutics Strategically collaborates with ProBio
ProBio and Neoletix Announce Successful Completion of 200-Liter GMP Production Runs of Recombinant Coagulation FVIII Based on a Novel Production Technology
SunRock Biopharma and ProBio Enter into a Collaboration Agreement to Develop Novel Monoclonal Antibody Program
ProBio Enters Collaboration with Singapore's Experimental Drug Development Centre to Develop Anti-Fibrosis Therapeutic Antibody Programme
ProBio and Neoletix signed a letter of intent on clinical and commercial production of recombinant human coagulation factor VIII
GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement
ProBio Congratulates EyeGene for Clinical Trial Approval for mRNA COVID-19 Vaccine in South Korea
ProBio Passed European Union Qualified Person (QP) Audit Successfully
ProBio and TG ImmunoPharma Enter into Collaboration on Innovative Antibody Drug Project
ProBio Named a Top 10 Drug Discovery Solution Provider in Asia-Pacific
China’s Largest Commercial GMP Plasmid Manufacturing Facility is Put into Operation, ProBio Expanding Manufacturing Capacity Again
ProBio and AbTis Enter into an Exclusive Worldwide License Agreement for ADC Targeting Claudin 18.2
Successful Groundbreaking Ceremony for ProBio to Expand Commercial cGMP Plasmid and Viral Vector Manufacturing Facility in Zhenjiang, China
ProBio initiates a CDMO contract for next-generation CD47 antibody with InnoBation Bio
National Cancer Center Japan and ProBio Enter Research Collaboration Agreement for a Plasmid & Lentiviral vector CMC development
ProBio Signs CDMO Supply Agreement And Forms Strategic Partnership with AffyXell Therapeutics – A Joint Daewong-Avacta Venture
Athenex Partners with Leading Contract Manufacturer ProBio in the Development of Advanced Cell and Gene Therapies
ProBio and ProteoNic BV Signed a Strategic Cooperation Based on High Expressing Vector System
ProBio Signs MOU to Form Strategic Partnership with ACT Therapeutics to Development of New CAR-T Cell Therapies
ProBio and DAAN Bio Therapeutics, Sign a Strategic Cooperation MOU for the Discovery and Development of Novel Drugs
ProBio Congratulates Selecxine on FDA Clearance of IND Application for Innovative Antibody Drug Program
ProBio Signs MOU to Form Strategic Partnership with GeneCraft To Development and Production of New AAV gene therapies
ProBio Enters Strategic Collaboration with Hibiocy Co. Ltd, the affiliate of Rojukiss International Public Company Limited (KISS) – the leading Thai-based Beauty & Health company, for the development and manufacturing of COVITRAP™ and future new
ProBio Licenses Novel Fc Silencing Technology from mAbsolve
A bispecific antibody molecule jointly developed by Buchang Pharmaceutical and REMD Biotherapeutics，partners of ProBio, received IND clearance from NMPA for clinical trial
Program CD47, provided the CMC service by ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp
ProBio Congratulates Selecxine’s IND Clearance from MFDS
A Joint Collaboration Between Bio Immunitas and ProBio Leads to the Development and Fast Track Manufacturing of A Novel Therapeutic Platform
ProBio and RVAC Medicines Announce Strategic Partnership for GMP Plasmid DNA Manufacturing for mRNA COVID-19 Vaccine Candidate
ProBio Congratulates Eutilex’s IND Clearance from MFDS
ProBio and Comprehensive Cell Solutions, a Business Unit of the New York Blood Center Enterprises, Form a Pioneering Partnership to Expedite Cell and Gene Therapy Development and Manufacturing
ProBio Congratulates IMBiologics on FDA Clearance of IND Application for Innovative Bispecific Antibody Drug Project (IMB-101)
Dx&Vx Signs Strategic Partnership with ProBio for Novel Drug Development
ProBio Congratulates ABL Bio’s IND Clearance of ABL103 Program from MFDS
ProBio Partners with Epi Biotech to Advance Hair Loss Antibody Therapy
The MOU between ProBio and NuclixBio
ProBio signs viral vector manufacturing MOU with Curocell for next-generation CAR-T therapy
ProBio Congratulates TG ImmunoPharma on FDA Clearance of Clinical Trial for TGI-5 Monoclonal Antibody
ProBio announces the appointment of Dr. Li Chen, as the Chief Executive Officer
ProBio Extends Congratulations to InnoBation Bio on MFDS Clearance of IBC101 Program
ProBio Signs Collaboration Agreement with Cell Resources Corporation, a Subsidiary of Alfresa Holdings Corporation for Cell Therapy Development
ProBio and UCI Therapeutics Sign a Strategic Cooperation MOU for Comprehensive Collaboration in Gene Delivery Technologies, Including Viral and Non-Viral Approaches
Resource Library
Handbooks
Webinars
Biologics Webinar Series
Our Heart Goes Out to You, Our Heroes in Combating COVID-19
Global Biologics and CGT Symposium 2023- South Korea
Learning Center
Global CGT Symposium 2024 - South Korea
Global Biologics Symposium 2024 - South Korea
About Us
Experience & Expertise
Careers
Partnership
Customer Group
Information Security
Privacy Policy
Standard Service Agreement
Cookies Policy
Quality Management
Capabilities & Capacity
Regulatory Affairs
Locations
Voice of Customer
Site Map
SAP system
ProBio - 日本語紹介
2024 GenScript Biotech Global Forum